

Saturday, October 24, 2015

	Hall A	Hall B
07:00-08:30	Plenary Session 11: *Industry Breakfast Symposium: IORT for early breast cancer: From clinical trials to clinical reality <i>Supported by ZEISS</i>	
08:30-10:00	Plenary Session 12: Controversies in adjuvant endocrine therapy	
10:00-10:30	<i>Coffee break and poster viewing</i>	
10:30-11:30	Parallel Session 13: Controversies in brain metastases	Parallel Session 14: Controversies in DCIS: Should all cases be treated?
11:30-13:00	Parallel Session 15: *Industry Symposium: Management of endocrine resistance <i>Supported by Novartis Oncology</i>	Parallel Session 16: Who is responsible for follow-up and survivorship care of women with early stage breast cancer?
13:00-14:30	<i>Lunch break and poster viewing</i>	
13:30-14:20	Case Discussion Panel	
14:30-15:30	Parallel Session 17: Controversies in breast reconstruction	Parallel Session 18: Controversies in advanced breast cancer
15:35-16:50	Plenary Session 19: Breast cancer 2020	
16:50-17:00	Congress closing and award presentation	

World Congress on Controversies in Breast Cancer

CONGRESS TIMETABLE



CoBRA



Melbourne, Australia
October 22-24, 2015

www.congressmed.com/cobra

 CongressMed
Powered by MCI Group

c/o MCI Geneva | 75 Rue de Lyon | C.P. 502 CH-1211 | Geneva 13 | Switzerland
Tel. +972 73 706 6950 | Fax. +972 3 725 6266
cobra@congressmed.com | www.congressmed.com/cobra

Thursday, October 22, 2015

Hall A	
17:45-18:00	Congress Opening
18:00-19:30	Plenary Session 1: Controversies in neoadjuvant chemotherapy
19:30	Networking Reception

*Session not included in main CME/CPD program

Friday, October 23, 2015

	Hall A	Hall B
08:30-10:00	Parallel Session 2: *Industry Symposium: Controversies in bone health <i>Supported by Amgen Oncology</i>	Parallel Session 3: Controversies in screening and imaging
10:00-10:30	<i>Coffee break and poster viewing</i>	
10:30-11:30	Parallel Session 4: Molecular profiling in early breast cancer: An important addition, or is a good pathologist enough?	Parallel Session 5: Free Communication Session
11:30-13:00	Parallel Session 6: *Industry Symposium: Controversies in HER2-positive disease <i>Supported by Roche Oncology</i>	Parallel Session 7: Breast Care Nurses - Care coordinators or agents of lifestyle change?
13:00-14:00	<i>Lunch break and poster viewing</i>	
14:00-15:30	Parallel Session 8: Controversies in adjuvant chemotherapy	Parallel Session 9: Controversies in breast conservation: Better surgery, better pathology, better radiotherapy?
15:30-16:00	<i>Coffee break and poster viewing</i>	
16:00-17:30	Plenary Session 10: Controversies in loco-regional management	



CoBRA